Shares digital

ProStrakan (PSK) – Finals PTP: -£17.6m (-£17.3m) Divi: n/a (n/a)

Anticipation of key product approvals this year has led to confidence that the drug development company will break even in 2009, with profits expected the following year.

Ceo Wilson Totten says that US approval of its chemotherapy product Sancuso is expected this year while a filing with the FDA for its pain treatment Cellegescic is planned for late this year or early next.

Sales of its existing products were also encouraging, with revenues for its transdermal testosterone gel Tostran up 256% in Europe.

Its cancer pain drug Rapinyl recently gained approval for the Swedish market and wider European approval, and more EU launches are expected this year.

The group had £24.5 million cash at the end of the period and a further £30 million available under a debt facility.

Shares says: This will be a pivotal year for the company and shares are worth holding on to.

by: Susanna Twidale